Compare
Kisqali vs. Kisqali Femara Co-Pack

Kisqali (ribociclib) is a medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It belongs to a drug class called CDK4/6 inhibitors, which help slow or stop cancer cells from growing. You typically take a tablet by mouth once a day for 21 days, then take 7 days off, repeating this 28-day cycle. It’s often taken together with other hormone treatments, like aromatase inhibitors or fulvestrant. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.

• Early breast cancer (HR+, HER2-), used with an aromatase inhibitor in adults at high risk of the cancer coming back
• Advanced or metastatic breast cancer (HR+, HER2-), used with
  • An aromatase inhibitor as the first hormone-based treatment OR
  • Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatment

Early breast cancer

• Lower white blood cell counts (up to 97%)
• Lower red blood cell counts (47%)
• Higher liver enzymes (up to 45%)
• Infections (37%)
• Higher creatinine levels (33%)
• Lower platelets (28%)
• Headache (23%)
• Nausea (23%)
• Tiredness (22%)

Advanced or metastatic breast cancer

• Lower white blood cell counts (up to 95%)
• Lower red blood cell counts (68%)
• Higher liver enzymes (up to 55%)
• Nausea (47%)
• Infections (47%)
• Higher creatinine levels (42%)
• Tiredness (35%)
• Low red blood cell count
• Lower appetite
• Dizziness
• Trouble sleeping
• Trouble breathing
• Swollen or sore mouth
• Stomach pain
• Fever
• Pain or swelling in arms or legs
• Liver problems
• Lower platelets (34%)
• Diarrhea (33%)
• Vomiting (29%)
• Headache (27%)
• Constipation (25%)
• Hair loss (25%)
• Cough (24%)
• Rash (24%)
• Back pain (24%)
• Lower blood sugar (20%)

Note: Side effects listed above were reported in studies where people took Kisqali (ribociclib) with another hormone medication.

• Lung problems
• Severe skin reactions
• Heart rhythm problem (QT prolongation)
• Liver problems
• Low white blood cell counts
• Harm to unborn baby

Kisqali Femara Co-Pack is a combination medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It contains two medications: Kisqali (ribociclib), a CDK4/6 inhibitor, and Femara (letrozole), an aromatase inhibitor. You take Kisqali once a day for 21 days, then take 7 days off, in a 28-day cycle. Femara is taken once a day with no breaks. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.

• Early breast cancer (HR+, HER2-) in adults at high risk of the cancer coming back
• Advanced or metastatic breast cancer (HR+, HER2-) as the first hormone-based treatment

Early breast cancer

• Lower white blood cell counts (up to 97%)
• Lower red blood cell counts (47%)
• Higher liver enzymes (up to 45%)
• Infections (37%)
• Higher creatinine levels (33%)
• Lower platelets (28%)
• Headache (23%)
• Nausea (23%)
• Tiredness (22%)

Advanced or metastatic breast cancer

• Lower white blood cell counts (up to 94%)
• Lower red blood cell counts (72%)
• Higher liver enzymes (up to 53%)
• Infections (46%)
• Nausea (46%)
• Tiredness (36%)
• Lower platelets (34%)
• Diarrhea (33%)
• Headache (29%)
• Hair loss (29%)
• Vomiting (29%)
• Back pain (25%)
• Constipation (25%)
• Cough (24%)
• Rash (22%)
• Higher creatinine levels (20%)
• Stomach pain (20%)

• Lung problems
• Severe skin reactions
• Heart rhythm problem (QT prolongation)
• Liver problems
• Low white blood cell counts
• Harm to unborn baby